Sami gets DCGI nod for phase III trials of Forskolin eye drops
Patients worried of getting blind due to glaucoma can now rejoice. Days are not far when thousands of them will have access to a cost-effective medicine to manage their fearsome eye disorder which hitherto made them irreversibly blind with the advancement of the disease, because of either being late in detecting it or of the lack of timely medical care due to the prohibitive cost of medicines.

German Remedies to market Bio Sidus’ oncology product in India
German Remedies, a wholly-owned subsidiary of Cadila Healthcare, has inked an agreement with Argentina-based Bio Sidus to market the latter’s oncology drug Colstim (filgrastim) in India.